PhRMA strikes a more conciliatory note

DTC ads can be “both a blessing and a curse,” and if companies fail to include messaging about patient assistance programs in them, “then your message is a resentful one.” To address the crisis of the uninsured, “some sort of government support for the uninsured” is much needed to replace “crisis medicine.”

Who said it? Bart Stupak? Peter Rost? Try PhRMA CEO Billy Tauzin, in interviews with DC blog The Politico. While not straying far from established talking points, Tauzin seems to be taking a more conciliatory tone as Democrats look poised to solidify their control of Congress and mount a strong challenge for the White House.

“We're never going to desert old friends, but I'm ready to make new ones every day,” said Tauzin. “I want to make sure people look at us and see us as patient advocates and not as Democrat or Republican.”

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.